(TheNewswire)
LONDON, ONTARIO - TheNewswire - April 6, 2021 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH ), a leading clinical-stageregenerative medicine therapeutics company, is pleased to announcethat lead principal investigator Dr. Piotr Witkowski and the ClinicalTrial Investigator Team for its US Phase I/II Type 1 Diabetes clinicaltrial will present data and observations from the ongoing study in aposter presentation at the upcoming American Diabetes Association’s(ADA) 81 st ScientificSessions to be held June 25 - 29, 2021.
The abstract will also be published online at the journal Diabetes® website and thepresentation will be available to conference attendees on Friday, June25, 2021.
Dr. Witkowski, Director, Pancreatic and Islet Transplant Program atthe University of Chicago, is also scheduled to deliver a lecturetitled “ Islet Transplantation –Benefits and Shortcomings”, as part of the Clinical and Regulatory Hurdles FacingIslet Transplantation session on Monday, June 28, 2021, at 8:00am ET.
Note : all information contained in the submittedabstract should be considered preliminary and subject to change untilthe study data and observations are fully presented at the ADA 81stScientific Sessions and is subject to embargo until June 25, 2021, at11:30 am ET.
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease. The CellPouch, along with therapeutic cells, has been shown to providelong-term safety and efficacy in small and large animal models ofdiabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutictechnologies using a medical device and immune protected therapeuticcells ( i.e. human donor cells, corrected human cells and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com .
ABOUT THE ADA’s SCIENTIFICSESSIONS
The American Diabetes Association’s (ADA) 81st Scientific Sessions,the world’s largest scientific meeting focused on diabetes research,prevention, and care, will be held virtually June 25-29, 2021. Leadingphysicians, scientists, and health care professionals from around theworld will unveil cutting-edge research, treatment recommendations andadvances toward a cure for diabetes. Though the conference will beremote this year, attendees will receive exclusive access to nearly2,000 original research presentations and take part in provocative andengaging exchanges with leading diabetes experts. Learn more andregister at scientificsessions.diabetes.org and join theScientific Sessions conversation on social media using #ADA2021.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.